Skip to main content
Kisqali patient portrayal.

KISQALI single-strength tablets make dose reduction simple and convenient

Reference: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hamilton E, Decker T, Rugo HS, et al. Impact of ribociclib dose reduction on efficacy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in NATALEE. Poster presented at: San Antonio Breast Cancer Symposium; December 10-13, 2024; San Antonio, TX. P1-11-16. 3. Hortobagyi GN, Lacko A, Sohn J, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025;36(2):149-157. doi:10.1016/j.annonc.2024.10.015